t(11;14)(q13;q32) IGH/CCND1

1998-05-01   Jean-Loup Huret 

1.Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France

Clinics and Pathology

Phenotype stem cell origin

B-cell non Hodgkin lymphoma of the low to intermediate grade

Epidemiology

annual incidence 5/106; median age: 65 yrs

Clinics

advanced disease

Prognosis

median survival: 3 to 4 yrs

Phenotype stem cell origin

chronic lymphoproliferative disorder affecting mature B-cells

Epidemiology

rare disease; median age 70 yrs

Clinics

patients often present with advanced stage disease

Prognosis

median survival: 3 yrs

Phenotype stem cell origin

proliferation involving plasma cells

Epidemiology

rare disorder

Prognosis

median survival is less than a yr

Phenotype stem cell origin

chronic B-cell lymphoproliferation

Epidemiology

rare disorder; median age: 70 yrs

Clinics

relatively benign clinical course

Prognosis

80% 5-yr survival

Disease

chronic lymphocytic leukaemia

Phenotype stem cell origin

chronic B-cell lymphoproliferation

Epidemiology

annual incidence 30/106; median age: 60-80 yrs

Clinics

often a slow evolutive disease

Prognosis

highly variable according to the staging: from staging A: survival not reduced compared to age matched population, to staging C: median survival of 2 yrs

Phenotype stem cell origin

malignant plasma cell proliferation (terminally differenciated B-cell)

Epidemiology

annual incidence: 30/106; median age: 60 yrs

Prognosis

median survival: 3 yrs.

Cytogenetics

Cytogenetics morphological

t(11;14) has earlier been thought to be the hallmark of the mantle cell lymphoma; actually, the frequency of t(11;14) is: 50-70% in mantle cell lymphoma, 10-20% in B-prolymphocytic leukaemia, in plasma cell leukaemia, and in splenic lymphoma with villous lymphocytes, and 2-5% in chronic lymphocytic leukaemia, and in multiple myeloma.

Cytogenetics molecular

in particular interphase cytogenetics, are relevant in these diseases with an usually low mitotic index

Additional anomalies

sole anomaly in only 10% of cases; part of a complex karyotype in 2/3 of cases; numerous recurrent anomalies found conjointly (which is the primary?), particularly: +3, +7, del(9p), +18, + mar, found in about 10% of cases each; other: del(1p), del(6q), del(7q), -8, +12, del(13q), del(17p)

Variants

three way complex t(11;14; Var) exist and showed that the crucial event lies on der(14)

Genes Involved and Proteins

Gene name
CCND1 (B-cell leukemia/lymphoma 1)
Location
11q13.3
Dna rna description
5 exons
Protein description
encodes the cyclin D1; role in the cell cycle control: G1 progression and G1/S transition
Gene name
IGH (Immunoglobulin Heavy)
Location
14q32.33

Result of the Chromosomal Anomaly

Description

5 BCL1 translocated on chromosome 14 near JH (junctions genes of IgH) and C in 3; the breakpoint in BCL1 is in MTC (major translocation cluster), centromeric to the gene (in 5), in 80% of cases, or dispersed in mTC1, 2, or 3 in 5of the gene or in the 3 untranslated region of exon 5.no fusion protein, but promoter exchange; the immunoglobulin gene enhancer stimulates the expression of BCL1

Oncogenesis

overexpression of BCL1 accelerates passage through the G1 phase.

Bibliography

Pubmed IDLast YearTitleAuthors
94522761998Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors.Bosch F et al
90782901997Genes and chromosomes in chronic B-cell leukemia.Crossen PE et al
90782871997Cytogenetics of lymphomas: a brief review of its theoretical and practical significance.Donner LR et al
90812011997Cytogenetics and molecular genetics in multiple myeloma.Feinman R et al
91788311997Prognostic factors in chronic lymphocytic leukemia.Hallek M et al
74974461995Overexpression of the PRAD1 oncogene in a patient with prolymphocytic leukemia with t(11;14)(q13;q32).Kobayashi H et al
91788431997Mantle cell lymphoma: diagnostic criteria, clinical aspects and therapeutic problems.Meusers P et al
87598961996The ultrastructure of mantle cell lymphoma and other B-cell disorders with translocation t(11;14)(q13;q32).Resnitzky P et al
84996401993Rearrangement and overexpression of the BCL-1/PRAD-1 gene in intermediate lymphocytic lymphomas and in t(11q13)-bearing leukemias.Rimokh R et al
92206671997Overexpression of PRAD1/cyclin D1 in plasma cell leukemia with t(11;14)(q13;q32).Shimazaki C et al

Summary

Fusion gene

IGH/CCND1 IGH (14q32.33) CCND1 (11q13.3) M ins(14;11)(q32;q13q13) t(11;14)(q13;q32) t(11;19;14)(q13;q13;q32) t(14;16)(q32;q23) t(14;20)(q32;q12) t(1;11;14)(q32;q13;q32) t(3;14;11)(q21;q32;q13) t(4;14)(p16;q32) t(6;14)(p21;q32)

Note

t(11;14) is mainly found in mantle cell lymphoma, but also in B-prolymphocytic leukaemia, in plasma cell leukaemia, in splenic lymphoma with villous lymphocytes, in chronic lymphocytic leukaemia, and in multiple myeloma, herein briefly described; all these diseases involve a B-lineage lymphocyte.
Atlas Image
t(11;14)(q13;q32) Top: G- banding - Courtesy Diane H. Norback, Eric B. Johnson, Sara Morrison-Delap Cytogenetics at theWaisman Center and R- banding: Third row - Editor; last row and FISH - Courtesy Hossein Mossafa.

Citation

Jean-Loup Huret

t(11;14)(q13;q32) IGH/CCND1

Atlas Genet Cytogenet Oncol Haematol. 1998-05-01

Online version: http://atlasgeneticsoncology.org/haematological/2021/t(11;14)(q13;q32)-igh-ccnd1

External Links